Low Systemic Exposure after Repeated Topical Application of Pimecrolimus (Elidel<sup>®</sup>, SD Z ASM 981) in Patients with Atopic Dermatitis

2002114 citationsJournal Article

Authors

E.J.M. van Leent · University of Amsterdam

Marie-Eve Ebelin · Novartis (Switzerland)

P Burtin · Novartis (Switzerland)

Birgit Dorobek · Novartis (Switzerland)

Phyllis I. Spuls · University of Amsterdam

Jan D. Bos · University of Amsterdam

Abstract

The 3-week twice daily treatment with pimecrolimus cream 1% results in consistently low pimecrolimus blood concentrations with no accumulation. Pimecrolimus cream appears suitable for the long-term management of atopic dermatitis.

Topics & Keywords

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Contact Dermatitis and Allergies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Dermatology

Volume 204, Issue 1, pp. 63-68

DOI: 10.1159/000051813

Field-Weighted Citation Impact: 14.56

Command Palette